Efficacy, safety, and pharmacokinetics of pumecitinib nasal spray for moderate-to-severe seasonal allergic rhinitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

Authors

Jingyun Li, Menglin Wang, Xu Zhang, Xueyan Wang, Xiangli Yang, Shiping Bao, Wen Liu, Jianbin Li, Qingyao Yuan, Fang Quan, Wei Chen, Lijia Wan, Hui Huangfu, Fengying Qiao, Shengli Wei, Yiqun Zhou, Zhendong Xu, Xiaoyong Ren, Haiyun Shi, Ying Wang, Yunpei Zhao, Daoliang Song, Hao Yang, Pengfei Zhang, Qianbo Cui, Qin Li, Yan Feng, Huixian Zhu, Linlin Han, Mancang Wang, Kang Zhu, Yan Li, Qi Guo, Daniel Y Du, Chengshuo Wang, Yuan Zhang, Luo Zhang

Published in

The Lancet regional health. Western Pacific. Volume 74. Pages 101969. Epub Aug 23, 2026.

Abstract

Seasonal allergic rhinitis (SAR) is a pollen-triggered condition causing nasal inflammation and quality of life impairment. Pumecitinib, a topical Janus kinase (JAK) inhibitor may modulate allergic inflammation. We evaluated the efficacy, safety, and pharmacokinetics of pumecitinib nasal spray administered over a 14-day period during the pollen season in patients with moderate-to-severe seasonal allergic rhinitis (SAR).
This phase 2, randomised, double-blind, placebo-controlled, parallel-group study was carried out at 20 centres in China. Adults aged 18-65 years with moderate-to-severe SAR were randomised 1:1:1:1 to receive placebo or pumecitinib nasal spray at doses of 0·2 mg, 1·2 mg, or 2·0 mg administered twice daily for 14 days. The primary efficacy endpoint was the mean change from baseline in daily reflective total nasal symptom score (rTNSS) over 14 days. The secondary endpoints included reflective total ocular symptoms (rTOSS), individual nasal and ocular symptoms, and rhinoconjunctivitis quality of life questionnaire (RQLQ) scores This study is registered with chitr.org.cn, ChiCTR2400081767, and is completed.
Between March 20 and June 5, 2024, 169 patients were randomly assigned and 168 received treatment (92 male, 76 female) and were included in the full analysis set. Both the 1·2 mg and 2·0 mg doses of pumecitinib demonstrated significant improvements compared with placebo in the mean change from baseline in the daily rTNSS over 14 days (least-squares [LS] mean difference -1·2 [95% CI -2·2 to -0·2], p = 0·021, and -1·2 [-2·2 to -0·2], p = 0·018, respectively). These two dosage groups significantly improved rTOSS, individual nasal and ocular symptoms, and RQLQ scores compared to the placebo group. Treatment-emergent adverse events (TEAEs) occurred in 15% (0·2 mg), 33% (1·2 mg), 21% (2·0 mg), and 24% (placebo) of patients; most were mild, with no clear dose-response relationship.
Pumecitinib 1·2 mg and 2·0 mg twice daily significantly alleviated nasal and ocular symptoms and improved quality of life in moderate-to-severe SAR, with a favourable safety profile during 14-day treatment. This provides proof of concept for topical JAK inhibition in SAR, warranting larger trials.
PrimeGenX Therapeutics Co., Ltd.

PMID:
42656228
Bibliographic data and abstract were imported from PubMed on 27 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.